Gene Therapy: Embarking on the Future Today
The advancement of cutting-edge, state-of-the-art therapeutic solutions stands as a highly sought-after field in the realm of biomedicine. Across the globe, hundreds of clinical trials are currently underway, assessing the safety and effectiveness of gene therapy products for combating severe inherited ailments including haemophilia, spinal muscular atrophy, Duchenne muscular dystrophy, various visual impairments, and lysosomal storage diseases, among others. Notably, several medications have already made their way into the market, while numerous other products showcase remarkable efficacy in addressing conditions that were previously deemed either incurable or arduous to treat. Are there any noteworthy scientific research endeavours taking place in the Russian Federation regarding the development of advanced therapy products, and how close are we to their implementation in clinical practice? Have Russian developers gained expertise in producing genetically modified biomedical cell products and oncolytic viruses? Are we capable of rivalling the world's leading bioengineering laboratories in terms of creating groundbreaking drugs for gene therapy? And, above all, how can we collaborate and support each other in achieving these ambitious yet highly coveted objectives?